Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 219
Filter
1.
Comput Methods Programs Biomed ; 151: 91-99, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28947009

ABSTRACT

BACKGROUND AND OBJECTIVE: The study follows the proposal of decomposing a given data matrix into a product of independent spatial and temporal component matrices. A multi-variate decomposition approach is presented, based on an approximate diagonalization of a set of matrices computed using a latent space representation. METHODS: The proposed methodology follows an algebraic approach, which is common to space, temporal or spatiotemporal blind source separation algorithms. More specifically, the algebraic approach relies on singular value decomposition techniques, which avoids computationally costly and numerically instable matrix inversion. The method is equally applicable to correlation matrices determined from second order correlations or by considering fourth order correlations. RESULTS: The resulting algorithms are applied to fMRI data sets either to extract the underlying fMRI components or to extract connectivity maps from resting state fMRI data collected for a dynamic functional connectivity analysis. Intriguingly, our algorithm shows increased spatial specificity compared to common approaches, while temporal precision stays similar. CONCLUSION: The study presents a novel spatiotemporal blind source separation algorithm, which is both robust and avoids parameters that are difficult to fine tune. Applied on experimental data sets, the new method yields highly confined and focused areas with least spatial extent in the retinotopy case, and similar results in the dynamic functional connectivity analyses compared to other blind source separation algorithms. Therefore, we conclude that our novel algorithm is highly competitive and yields results, which are superior or at least similar to existing approaches.


Subject(s)
Algorithms , Brain/diagnostic imaging , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Connectome , Humans
2.
J Affect Disord ; 160: 27-33, 2014 May.
Article in English | MEDLINE | ID: mdl-24709019

ABSTRACT

BACKGROUND: There is some controversy but growing evidence that childhood onset bipolar disorder may be more prevalent and run a more difficult course in the United States than some European countries. METHODS: We update and synthesize course of illness data from more than 960 outpatients with bipolar disorder (average age 40) from 4 sites in the U.S. and 3 sites in Netherlands and Germany. After giving informed consent, patients reported on parental history, childhood and lifetime stressors, comorbidities, and illness characteristics. RESULTS: Almost all aspects of bipolar disorder were more adverse in patients from the US compared with Europe, including a significantly higher prevalence of: bipolar disorder in one parent and a mood disorder in both parents; childhood verbal, physical, or sexual abuse; stressors in the year prior to illness onset and the last episode; childhood onsets of bipolar illness; delay to first treatment; anxiety disorder, substance abuse, and medical comorbidity; mood episodes and rapid cycling; and nonresponse to prospective naturalistic treatment. LIMITATIONS: Selection bias in the recruit of patients cannot be ruled out, but convergent data in the literature suggest that this does not account for the findings. Potential mechanisms for the early onset and more adverse course in the U.S. have not been adequately delineated and require further investigation. CONCLUSIONS: The data suggest the need for earlier and more effective long-term treatment intervention in an attempt to ameliorate this adverse course and its associated heavy burden of psychiatric and medical morbidity.


Subject(s)
Bipolar Disorder/epidemiology , Bipolar Disorder/therapy , Health Policy , Adult , Age of Onset , Cross-Sectional Studies , Female , Germany/epidemiology , Humans , Interview, Psychological , Male , Netherlands/epidemiology , United States/epidemiology
3.
Acta Psychiatr Scand ; 129(5): 375-82, 2014 May.
Article in English | MEDLINE | ID: mdl-24138298

ABSTRACT

OBJECTIVE: Early-onset bipolar (BP) disorder and other poor prognosis characteristics are more prevalent in patients from the United States than from the Netherlands and Germany (abbreviated as Europe). We explored the impact of parental loading for affective illness on onset and other characteristics of BP disorder. METHOD: Parental history for unipolar (UP) and bipolar (BP) depression and course of illness characteristics were obtained from self-report in adults (average age 42) with BP disorder. Illness characteristics were examined by χ2 and multinomial logistic regression in relationship to the degree of parental loading: i) both parents negative; ii) one UP disorder; iii) one with BP disorder; and iv) both affected. RESULTS: After controlling for many poor prognosis factors, compared with those from Europe, patients from the United States had more iii) one parent with BP disorder and iv) both parents affected. An early age of onset of BP disorder was independently associated with this increased parental loading for affective disorder. CONCLUSION: Parental history of BP disorder and both parents with a mood disorder were more common in the United States than Europe and were associated with an early onset of bipolar disorder and other poor prognosis characteristics. These findings deserve replication and exploration of the potential mechanisms involved and their therapeutic implications.


Subject(s)
Affective Symptoms , Bipolar Disorder , Child of Impaired Parents/psychology , Parents/psychology , Adult , Affective Symptoms/diagnosis , Affective Symptoms/ethnology , Age of Onset , Bipolar Disorder/diagnosis , Bipolar Disorder/ethnology , Bipolar Disorder/psychology , Cross-Cultural Comparison , Depressive Disorder , Family Health/ethnology , Female , Germany/epidemiology , Humans , Male , Netherlands/epidemiology , Prevalence , Prognosis , Psychiatric Status Rating Scales , Risk Factors , Self Report , United States/epidemiology
4.
Psychol Med ; 43(8): 1625-37, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23075829

ABSTRACT

BACKGROUND: Lack of coordination between screening studies for common mental disorders in primary care and community epidemiological samples impedes progress in clinical epidemiology. Short screening scales based on the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI), the diagnostic interview used in community epidemiological surveys throughout the world, were developed to address this problem. METHOD: Expert reviews and cognitive interviews generated CIDI screening scale (CIDI-SC) item pools for 30-day DSM-IV-TR major depressive episode (MDE), generalized anxiety disorder (GAD), panic disorder (PD) and bipolar disorder (BPD). These items were administered to 3058 unselected patients in 29 US primary care offices. Blinded SCID clinical reinterviews were administered to 206 of these patients, oversampling screened positives. RESULTS: Stepwise regression selected optimal screening items to predict clinical diagnoses. Excellent concordance [area under the receiver operating characteristic curve (AUC)] was found between continuous CIDI-SC and DSM-IV/SCID diagnoses of 30-day MDE (0.93), GAD (0.88), PD (0.90) and BPD (0.97), with only 9-38 questions needed to administer all scales. CIDI-SC versus SCID prevalence differences are insignificant at the optimal CIDI-SC diagnostic thresholds (χ2 1 = 0.0-2.9, p = 0.09-0.94). Individual-level diagnostic concordance at these thresholds is substantial (AUC 0.81-0.86, sensitivity 68.0-80.2%, specificity 90.1-98.8%). Likelihood ratio positive (LR+) exceeds 10 and LR- is 0.1 or less at informative thresholds for all diagnoses. CONCLUSIONS: CIDI-SC operating characteristics are equivalent (MDE, GAD) or superior (PD, BPD) to those of the best alternative screening scales. CIDI-SC results can be compared directly to general population CIDI survey results or used to target and streamline second-stage CIDIs.


Subject(s)
Anxiety Disorders/diagnosis , Mass Screening/instrumentation , Mood Disorders/diagnosis , Psychiatric Status Rating Scales/standards , Psychometrics/instrumentation , Adult , Anxiety Disorders/epidemiology , Diagnostic and Statistical Manual of Mental Disorders , Humans , Mass Screening/standards , Mood Disorders/epidemiology , Pilot Projects
5.
Mol Psychiatry ; 17(8): 818-26, 2012 Jul.
Article in English | MEDLINE | ID: mdl-21769101

ABSTRACT

Because of the high costs associated with ascertainment of families, most linkage studies of Bipolar I disorder (BPI) have used relatively small samples. Moreover, the genetic information content reported in most studies has been less than 0.6. Although microsatellite markers spaced every 10 cM typically extract most of the genetic information content for larger multiplex families, they can be less informative for smaller pedigrees especially for affected sib pair kindreds. For these reasons we collaborated to pool family resources and carried out higher density genotyping. Approximately 1100 pedigrees of European ancestry were initially selected for study and were genotyped by the Center for Inherited Disease Research using the Illumina Linkage Panel 12 set of 6090 single-nucleotide polymorphisms. Of the ~1100 families, 972 were informative for further analyses, and mean information content was 0.86 after pruning for linkage disequilibrium. The 972 kindreds include 2284 cases of BPI disorder, 498 individuals with bipolar II disorder (BPII) and 702 subjects with recurrent major depression. Three affection status models (ASMs) were considered: ASM1 (BPI and schizoaffective disorder, BP cases (SABP) only), ASM2 (ASM1 cases plus BPII) and ASM3 (ASM2 cases plus recurrent major depression). Both parametric and non-parametric linkage methods were carried out. The strongest findings occurred at 6q21 (non-parametric pairs LOD 3.4 for rs1046943 at 119 cM) and 9q21 (non-parametric pairs logarithm of odds (LOD) 3.4 for rs722642 at 78 cM) using only BPI and schizoaffective (SA), BP cases. Both results met genome-wide significant criteria, although neither was significant after correction for multiple analyses. We also inspected parametric scores for the larger multiplex families to identify possible rare susceptibility loci. In this analysis, we observed 59 parametric LODs of 2 or greater, many of which are likely to be close to maximum possible scores. Although some linkage findings may be false positives, the results could help prioritize the search for rare variants using whole exome or genome sequencing.


Subject(s)
Bipolar Disorder/genetics , Genetic Linkage/genetics , Genetic Predisposition to Disease/genetics , Genome-Wide Association Study/statistics & numerical data , Psychotic Disorders/genetics , Bipolar Disorder/complications , Depressive Disorder, Major/genetics , Genome-Wide Association Study/methods , Genotype , Humans , Pedigree , Polymorphism, Single Nucleotide/genetics , Psychotic Disorders/complications , White People/genetics
6.
J Affect Disord ; 112(1-3): 36-49, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18835043

ABSTRACT

OBJECTIVES: To evaluate the efficacy and safety of aripiprazole as acute and maintenance of effect monotherapy for acute bipolar mania. METHODS: Patients with acute bipolar I mania (DSM-IV-TR: YMRS > or =20), manic or mixed (with or without psychotic features) were randomized to double-blind aripiprazole (15-30 mg/day; n=155), placebo (n=165) or lithium (900-1500 mg/day; n=160) (1:1:1) for 3 weeks. Aripiprazole- and lithium-treated patients remained on blinded treatment for 9 additional weeks. The primary outcome was the mean change from baseline in YMRS Total score (LOCF) to Week 3. Secondary outcomes included the mean change from baseline in YMRS Total score (LOCF) at all other timepoints up to Week 12. RESULTS: Aripiprazole demonstrated significantly greater improvement than placebo in mean YMRS Total score from baseline to Day 2 (-4.3 vs.-2.8; p=0.003), and up to Week 3 (-12.6 vs. -9.0; p<0.001). Significant improvement in YMRS Total score was also seen with lithium versus placebo at Week 3 (-12.0 vs. -9.0; p=0.005). Improvements in YMRS Total score were maintained to Week 12 for aripiprazole (-14.5) and lithium (-12.7). Response rates at Week 3 were significantly higher with aripiprazole (46.8%) and lithium (45.8%) than placebo (34.4%; both p<0.05, LOCF); increasing to Week 12 with aripiprazole (56.5%) and lithium (49.0%). Most common adverse events with aripiprazole were headache, nausea, akathisia, sedation, and constipation; with lithium were nausea, headache, constipation, and tremor. CONCLUSIONS: Aripiprazole provided statistically significant improvement of acute mania within 2 days, continuing over 3 weeks and sustained over 12 weeks. The magnitude of improvement to Week 12 was similar with aripiprazole and lithium.


Subject(s)
Antipsychotic Agents/therapeutic use , Bipolar Disorder/drug therapy , Piperazines/therapeutic use , Quinolones/therapeutic use , Acute Disease , Adolescent , Adult , Aged , Antipsychotic Agents/adverse effects , Aripiprazole , Bipolar Disorder/diagnosis , Bipolar Disorder/psychology , Diagnostic and Statistical Manual of Mental Disorders , Double-Blind Method , Female , Follow-Up Studies , Headache/chemically induced , Humans , Lithium Compounds/adverse effects , Lithium Compounds/therapeutic use , Male , Middle Aged , Nausea/chemically induced , Piperazines/adverse effects , Placebos , Psychiatric Status Rating Scales/statistics & numerical data , Quinolones/adverse effects , Severity of Illness Index , Treatment Outcome , Weight Gain
7.
J Psychiatr Res ; 42(9): 787-9, 2008 Jul.
Article in English | MEDLINE | ID: mdl-17888452

ABSTRACT

The insulin secretogogue glucagon like peptide-1 (GLP-1), as well as agents which enhance GLP-1 signaling, are being studied as potential treatments for diabetes. Pre-clinical evidence suggests that these agents may have neuropsychiatric side effects; however, there have been no investigations or reports of these effects in humans. We evaluated possible anxiogenic and panicogenic properties of GLP-1 in 9 healthy subjects (age 47+/-8 years) and 7 patients with panic disorder (age 38+/-17 years) using a single-blinded intravenous GLP-1 challenge (2pmol/kg/min over 60min). We assessed the occurrence of panic attacks during and after GLP-1 infusion and the emergence of anxiety or panic symptoms using the Acute Panic Inventory (API). No patient or healthy subject experienced any panic attacks at any point during this study. Moreover, there were no significant changes in API scores following the infusion in either group. These data suggest that in humans, intraveneously administered GLP-1 does not appear to have anxiogenic or panicogenic properties, even in patients at highest risk for such reactions.


Subject(s)
Affect/drug effects , Anxiety Disorders/diagnosis , Anxiety Disorders/epidemiology , Glucagon-Like Peptide 1/pharmacology , Panic Disorder/diagnosis , Panic Disorder/epidemiology , Blood Glucose/analysis , Diagnostic and Statistical Manual of Mental Disorders , Female , Glucagon-Like Peptide 1/administration & dosage , Humans , Infusions, Intravenous , Male , Middle Aged , Severity of Illness Index , Signal Transduction/drug effects , Single-Blind Method
8.
Acta Psychiatr Scand ; 115(5): 360-5, 2007 May.
Article in English | MEDLINE | ID: mdl-17430413

ABSTRACT

OBJECTIVE: To compare the efficacy and tolerability of tranylcypromine vs. lamotrigine in bipolar depression not responding to conventional antidepressants. METHOD: Bipolar depressed patients received open randomized treatment with tranylcypromine or lamotrigine as add-on to a mood stabilizer during 10 weeks. In a second treatment phase, non-responding patients could receive the opposite drug. Outcome criteria were response (measured with CGI-BP and IDS-C), switch into mania, and completion of the study. RESULTS: Only 20 of 70 planned patients were randomized, due to problems with recruitment, and 19 patients received any medication. During the first treatment phase 5/8 patients (62.5%) responded to tranylcypromine without switch into mania, compared with 4/11 patients (36.4%) on lamotrigine with two switches (statistically not significant). Over both treatment phases, 8/10 patients (80%) receiving tranylcypromine completed the study vs. 5/13 (38.5%) on lamotrigine (likelihood 0.02). CONCLUSION: There still appears to be a role for tranylcypromine in the treatment of refractory bipolar depression. Larger controlled studies are demanded.


Subject(s)
Anticonvulsants/therapeutic use , Antidepressive Agents/therapeutic use , Bipolar Disorder/drug therapy , Tranylcypromine/therapeutic use , Triazines/therapeutic use , Adult , Anticonvulsants/adverse effects , Antidepressive Agents/adverse effects , Bias , Bipolar Disorder/diagnosis , Bipolar Disorder/psychology , Female , Humans , Lamotrigine , Male , Middle Aged , Patient Satisfaction , Patient Selection , Personality Assessment , Sample Size , Tranylcypromine/adverse effects , Treatment Outcome , Triazines/adverse effects
9.
Eat Weight Disord ; 12(1): e19-23, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17384521

ABSTRACT

OBJECTIVE: This study examined whether obese males with binge eating disorder (BED) seeking weight loss treatment differed significantly from obese females with BED seeking weight loss treatment in developmental variables, weight loss history, current and lifetime prevalence of psychiatric disorders, and metabolic abnormalities. METHODS: Psychiatric (using the Structural Clinical Interview for DSM-IV), medical, and laboratory assessments of 44 obese males with BED were compared with assessments from 44 age- and race-matched obese females with BED seeking weight loss treatment. RESULTS: High rates of mood disorders, anxiety disorders, and metabolic syndrome were observed in the population as a whole. Obese males with BED had attempted significantly fewer diets, medications and supplements for weight loss before seeking weight loss treatment. The two genders did not differ significantly in any other of the examined variables. CONCLUSIONS: Our results suggest that while obese men and women with BED who present for weight management are very similar, males had fewer previous attempts at weight loss, possibly related to their less pronounced body dissatisfaction or fewer help-seeking behaviors as compared to females. Our results also support findings of substantial comorbidity among obesity, BED, mood and anxiety disorders, and metabolic syndrome in weight loss seeking populations, in men as well as women.


Subject(s)
Bulimia Nervosa/psychology , Health Behavior , Obesity/psychology , Obesity/therapy , Adult , Body Image , Diet, Reducing , Female , Humans , Male , Middle Aged , Obesity/metabolism , Retrospective Studies , Sex Factors , Weight Loss
10.
Br J Psychiatry ; 189: 124-31, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16880481

ABSTRACT

BACKGROUND: Few studies have examined the relative risks of switching into hypomania or mania associated with second-generation antidepressant drugs in bipolar depression. AIMS: To examine the relative acute effects of bupropion, sertraline and venlafaxine as adjuncts to mood stabilisers. METHOD: In a 10-week trial, participants receiving out-patient treatment for bipolar disorder (stratified for rapid cycling) were randomly treated with a flexible dose of one of the antidepressants, or their respective matching placebos, as adjuncts to mood stabilisers. RESULTS: A total of 174 adults with bipolar disorder I, II or not otherwise specified, currently in the depressed phase, were included. All three antidepressants were associated with a similar range of acute response (49-53%) and remission (34-41%). There was a significantly increased risk of switches into hypomania or mania in participants treated with venlafaxine compared with bupropion or sertraline. CONCLUSIONS: More caution appears indicated in the use of venlafaxine rather than bupropion or sertraline in the adjunctive treatment of bipolar depression, especially if there is a prior history of rapid cycling.


Subject(s)
Antidepressive Agents/adverse effects , Bipolar Disorder/drug therapy , Bupropion/adverse effects , Cyclohexanols/adverse effects , Sertraline/adverse effects , Adjuvants, Pharmaceutic/adverse effects , Adult , Affect , Antidepressive Agents, Second-Generation/adverse effects , Bipolar Disorder/psychology , Depressive Disorder/chemically induced , Double-Blind Method , Female , Humans , Male , Risk Factors , Severity of Illness Index , Treatment Outcome , Venlafaxine Hydrochloride
11.
Int Clin Psychopharmacol ; 19(3): 173-4, 2004 May.
Article in English | MEDLINE | ID: mdl-15107662

ABSTRACT

Quetiapine, a new atypical antipsychotic, was added to ongoing treatment of bipolar I outpatients (n=15) for symptoms of illness (mood lability, irritability, psychosis and/or difficulty sleeping). All evaluations were prospectively obtained, with the majority of patients (n=9) showing much or very much improvement on the Clinical Global Impression for Bipolar Disorder (CGI-BP). Somatic complaints were limited. Mean (SD) duration before changes in medication regimens was 134 (100) days. Studies of the use of quetiapine in maintenance treatment of bipolar disorder are warranted.


Subject(s)
Antipsychotic Agents/therapeutic use , Bipolar Disorder/drug therapy , Dibenzothiazepines/therapeutic use , Antipsychotic Agents/adverse effects , Dibenzothiazepines/adverse effects , Dose-Response Relationship, Drug , Humans , Prospective Studies , Psychiatric Status Rating Scales , Quetiapine Fumarate , Treatment Outcome
12.
Cochrane Database Syst Rev ; (3): CD004040, 2003.
Article in English | MEDLINE | ID: mdl-12918000

ABSTRACT

BACKGROUND: Olanzapine, an atypical antipsychotic, is used in the treatment of mania both as monotherapy and combined with other medicines. OBJECTIVES: To review the efficacy and tolerability of olanzapine in the treatment of mania SEARCH STRATEGY: The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR), The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, CINAHL and PsycINFO were searched. SELECTION CRITERIA: Randomised trials comparing olanzapine with placebo or other drug in acute manic or mixed episodes. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data from trial reports MAIN RESULTS: Six trials (1422 participants) were included in the review. There was a high rate of failure to complete treatment on all treatments which may have biased the estimates of relative efficacy. Olanzapine was superior to placebo at reducing manic symptoms as monotherapy (Young Mania Rating Scale (YMRS) - weighted mean difference (WMD): -5.94, 95% CI -9.09 to -2.80) and in combination with lithium/valproate (YMRS) (WMD -4.01, 95% confidence interval -6.06 to -1.96). Olanzapine monotherapy was superior at reducing psychotic symptoms (PANSS positive symptoms subscale WMD: -3.54, 95% CI -5.28 to -1.80). Olanzapine was superior to divalproex at reducing manic symptoms (standardised mean difference (SMD): -0.29, 95% CI -0.50 to -0.08). Olanzapine did not lead to a statistically higher rate of clinical response than haloperidol (RR: 1.03, 95% CI 0.77 to 1.38). Fewer patients discontinued treatment on olanzapine than placebo (RR: 0.62, 95% CI 0.48 to 0.80). Olanzapine caused greater weight gain than placebo (WMD 1.91Kg, 95% CI 1.29 to 2.53) and somnolence (RR: 2.13 95% CI 1.62 to 2.79) but not more depressive symptoms (RR: 0.95, 95% CI 0.65 to 1.40) or movement disorder (WMD: -0.33, 95% CI -0.74 to 0.09). Olanzapine caused more prolactin elevation than placebo (RR: 4.35 95%CI 1.77 to 10.70). Olanzapine caused greater weight gain (WMD: 1.54, 95% CI 1.02 to 2.05); somnolence (RR: 1.80 95% CI 1.32 to 2.46) and movement disorders (SAS - WMD: 0.72 95% CI 0.11 to 1.33) than divalproex but less nausea ( RR: 0.36 95% CI 0.20 to 0.65). Olanzapine caused more weight gain than haloperidol (RR: 3.59, 95% CI 1.49 to 8.64) but less movement disorder (EPS RR: 0.10, 95% CI 0.04 to 0.24). REVIEWER'S CONCLUSIONS: Olanzapine is an effective treatment for mania and may be more efficacious than divalproex, though leads to more weight gain. Clinicians should consider both the relative efficacy and the different incidence of specific adverse effects of available drugs.


Subject(s)
Antipsychotic Agents/therapeutic use , Bipolar Disorder/drug therapy , Pirenzepine/analogs & derivatives , Pirenzepine/therapeutic use , Benzodiazepines , Drug Therapy, Combination , Humans , Olanzapine , Randomized Controlled Trials as Topic , Treatment Failure
13.
Mol Psychiatry ; 8(5): 546-57, 2003 May.
Article in English | MEDLINE | ID: mdl-12808434

ABSTRACT

In a genome-wide linkage survey, we have previously shown evidence suggesting that the chromosome 22q12 region contains a susceptibility locus for bipolar disorder (BPD). Two independent family sets yielded lod scores suggestive of linkage at markers in this region near the gene G protein receptor kinase 3 (GRK3). GRK3 is an excellent candidate risk gene for BPD since GRK3 is expressed widely in the brain, and since GRKs play key roles in the homologous desensitization of G protein-coupled receptor signaling. We have also previously shown GRK3 expression to be induced by amphetamine in an animal model of mania using microarray-based expression profiling. To identify possible functional mutations in GRK3, we sequenced the putative promoter region, all 21 exons, and intronic sequence flanking each exon, in 14-22 individuals with BPD. We found six sequence variants in the 5'-UTR/promoter region, but no coding or obvious splice variants. Transmission disequilibrium analyses of one set of 153 families indicated that two of the 5'-UTR/promoter variants are associated with BPD in families of northern European Caucasian ancestry. A supportive trend towards association to one of these two variants (P-5) was then subsequently obtained in an independent sample of 237 families. In the combined sample, the P-5 variant had an estimated allele frequency of 3% in bipolar subjects, and displayed a transmission to non-transmission ratio of 26 : 7.7 (chi(2)=9.6, one-sided P value=0.0019). Altogether, these data support the hypothesis that a dysregulation in GRK3 expression alters signaling desensitization, and thereby predisposes to the development of BPD.


Subject(s)
Bipolar Disorder/genetics , Chromosomes, Human, Pair 22 , Linkage Disequilibrium , Polymorphism, Single Nucleotide , Protein Serine-Threonine Kinases/genetics , Animals , Base Sequence , G-Protein-Coupled Receptor Kinase 3 , Genome, Human , Humans , Mice , Molecular Sequence Data , Phenotype , Promoter Regions, Genetic/genetics
14.
Mol Psychiatry ; 8(5): 558-64, 2003 May.
Article in English | MEDLINE | ID: mdl-12808435

ABSTRACT

Bipolar (BP) disorder or manic depressive illness is a major psychiatric disorder for which numerous family, twin and adoption studies support a substantial genetic contribution. Recently, we reported the results of a genome-wide search for BP disorder susceptibility loci in 20 pedigrees. Suggestive evidence for linkage was found in this study at three markers on 13q, representing possibly two peaks separated by 18 cM. We have now collected a second set of 32 pedigrees segregating BP disorder and have tested for evidence of linkage to markers on human chromosome 13q. In this sample, we have replicated the linkage result in 13q32 at D13S154 (lod=2.29), the more proximal of the two original peaks. When all 52 pedigrees were combined, the multipoint maximum lod score peaked approximately 7 cM proximal to D13S154 (lod=3.40), with a second peak occurring between D13S225 and D13S796 (lod=2.58). There have been several other reports of significant linkage to both BP disorder and schizophrenia in this region of chromosome 13. These pedigrees provide additional evidence for at least one locus for BP disorder in 13q32, and are consistent with other reports of a possible genetic overlap between these disorders.


Subject(s)
Bipolar Disorder/genetics , Chromosomes, Human, Pair 13 , Genetic Linkage , Chromosome Mapping , Genetic Predisposition to Disease , Humans , Pedigree
15.
Mol Psychiatry ; 7 Suppl 1: S8-14, 2002.
Article in English | MEDLINE | ID: mdl-11986990

ABSTRACT

The term 'mood stabilizer' has been applied to a number of medications for the treatment of patients with bipolar disorder. The operational definition of the properties of a mood-stabilizing medication has varied according to the properties of specific medications and the clinical characteristics of the illness. Randomized controlled trials of agents accepted or proposed as mood stabilizers are reviewed to marshall the available evidence in support of this claim. In addition, potential pharmacological mechanisms underlying mood-stabilizing effects of established compounds are reviewed.


Subject(s)
Affect/physiology , Antipsychotic Agents/therapeutic use , Mood Disorders/therapy , Affect/drug effects , Humans
16.
Mol Psychiatry ; 7(2): 165-73, 2002.
Article in English | MEDLINE | ID: mdl-11840309

ABSTRACT

The dopamine transporter gene (DAT) has been implicated in a variety of disorders, including bipolar disorder, attention-deficit hyperactivity disorder, cocaine-induced paranoia, Tourette's syndrome, and Parkinson's disease. As no clear functional polymorphism has been identified to date, studies rely on linkage disequilibrium (LD) to assess the possible genetic contribution of DAT to the various disorders. A better understanding of the complex structure of LD across the gene is thus critical for an accurate interpretation of the results of such studies, and may facilitate the mapping of the actual functional variants. In the process of characterizing the extent of variation within the DAT gene, we have identified a number of single nucleotide polymorphisms (SNPs) suitable for LD studies, 14 of which have been analyzed, along with a 3' repeat polymorphism, in a sample of 120 parent-proband triads. Calculations of pairwise LD between the SNPs in the parental haplotypes revealed a high degree of LD (P < 0.00001) in the 5' (distal promoter through intron 6) and 3' (exon 9 through exon 15) regions of DAT. This segmental LD pattern is maintained over approximately 27 kb and 20 kb in these two regions, respectively, with very little significant LD between them, possibly due to the presence of a recombination hotspot located near the middle of the gene. These analyses of the DAT gene thus reveal a complex structure resulting from both recombination and mutation, knowledge of which may be invaluable to the design of future studies.


Subject(s)
Linkage Disequilibrium , Membrane Glycoproteins , Membrane Transport Proteins/genetics , Nerve Tissue Proteins , Dopamine Plasma Membrane Transport Proteins , Family Health , Genetic Variation , Haplotypes , Humans , Polymorphism, Single Nucleotide
17.
Expert Opin Pharmacother ; 2(6): 1033-42, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11585006

ABSTRACT

This paper reviews the clinical pharmacology, efficacy and safety of the new atypical antipsychotic, ziprasidone. All published citations regarding ziprasidone were retrieved and reviewed using a MEDLINE search (completed for citations to early 2001). In addition, abstracts from recent scientific meetings presenting data not yet published were reviewed. Like other new antipsychotic medications, ziprasidone fits the profile of an atypical agent, exerting efficacy in positive and negative symptoms of psychosis, as well as affective symptoms, with a low risk of neurological and neuroendocrinological side effects. Unlike newer agents, it does not appear to be associated with weight gain in most patients.


Subject(s)
Antipsychotic Agents/therapeutic use , Piperazines/therapeutic use , Schizophrenia/drug therapy , Thiazoles/therapeutic use , Benzodiazepines , Clinical Trials as Topic , Dibenzothiazepines/therapeutic use , Dopamine Antagonists/therapeutic use , Drug Interactions , Guidelines as Topic , Humans , Olanzapine , Piperazines/adverse effects , Piperazines/pharmacokinetics , Pirenzepine/analogs & derivatives , Pirenzepine/therapeutic use , Quetiapine Fumarate , Risperidone/therapeutic use , Serotonin Antagonists/therapeutic use , Thiazoles/adverse effects , Thiazoles/pharmacokinetics , Time Factors , Tourette Syndrome/drug therapy
18.
Am J Psychiatry ; 158(8): 1227-30, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11481155

ABSTRACT

OBJECTIVE: Despite evidence of hyperresponsive peripheral and central nervous system (CNS) noradrenergic activity in posttraumatic stress disorder (PTSD), direct measures of CNS norepinephrine in PTSD have been lacking. The goal of this study was to determine serial CSF norepinephrine levels in patients with PTSD. METHOD: CSF samples were obtained serially over a 6-hour period in 11 male combat veterans with chronic PTSD and eight healthy men through an indwelling subarachnoid catheter. Thus the authors were able to determine hourly CSF norepinephrine concentrations under baseline (unstressed) conditions. Severity of the patients' PTSD symptoms was assessed with the Clinician-Administered PTSD Scale. RESULTS: CSF norepinephrine concentrations were significantly higher in the men with PTSD than in the healthy men. Moreover, CSF norepinephrine levels strongly and positively correlated with the severity of PTSD symptoms. Plasma norepinephrine concentrations showed no significant relationship with the severity of PTSD symptoms. CONCLUSIONS: These findings reveal the presence of greater CNS noradrenergic activity under baseline conditions in patients with chronic PTSD than in healthy subjects and directly link this pathophysiologic observation with the severity of the clinical posttraumatic stress syndrome.


Subject(s)
Norepinephrine/cerebrospinal fluid , Stress Disorders, Post-Traumatic/cerebrospinal fluid , Adult , Analysis of Variance , Catheters, Indwelling , Chromatography, High Pressure Liquid , Circadian Rhythm , Headache Disorders , Humans , Male , Middle Aged , Psychiatric Status Rating Scales/statistics & numerical data , Spinal Puncture/methods , Stress Disorders, Post-Traumatic/diagnosis , Subarachnoid Space
19.
J Clin Psychopharmacol ; 21(4): 360-8, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11476119

ABSTRACT

The relative efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder was studied. Sixty-two patients (29 depressed type; 33 bipolar type) entered a three-site, randomized, double-blind, 6-week trial of risperidone (up to 10 mg/day) or haloperidol (up to 20 mg/day). Trained raters assessed baseline, weekly, and end-of-study levels of psychopathology with the Positive and Negative Syndrome Scale (PANSS), the 24-item Hamilton Rating Scale for Depression (HAM-D-24) and the Clinician-Administered Rating Scale for Mania (CARS-M). The authors were unable to statistically distinguish between risperidone and haloperidol in the amelioration of psychotic and manic symptoms. In addition, there was no difference in worsening of mania between the two agents in either subgroup (i.e., depressed or bipolar subgroups). For the total PANSS, risperidone produced a mean decrease of 16 points from baseline compared with a 14-point decrease with haloperidol. For the total CARS-M scale, risperidone and haloperidol produced mean change scores of 5 and 8 points, respectively, and for the CARS-M Mania subscale, 3 and 7 points, respectively. Additionally, risperidone produced a mean decrease of 13 points from the baseline 24-item HAM-D, compared with an 8-point decrease with haloperidol. In those patients who had more severe depressive symptoms (i.e., HAM-D baseline score >20), risperidone produced at least a 50% mean improvement in 12 (75%) of 16 patients in comparison to 8 (38%) of 21 patients receiving haloperidol. Haloperidol produced significantly more extrapyramidal side effects and resulted in more dropouts caused by any side effect. There was no difference between risperidone and haloperidol in reducing both psychotic and manic symptoms in this group of patients with schizoaffective disorder. Risperidone did not demonstrate a propensity to precipitate mania and was better tolerated than haloperidol. In those subjects with higher baseline HAM-D scores (i.e., >20), risperidone produced a greater improvement in depressive symptoms than haloperidol.


Subject(s)
Antipsychotic Agents/therapeutic use , Haloperidol/therapeutic use , Psychotic Disorders/drug therapy , Risperidone/therapeutic use , Adult , Antipsychotic Agents/adverse effects , Bipolar Disorder/drug therapy , Bipolar Disorder/psychology , Depressive Disorder/drug therapy , Depressive Disorder/psychology , Double-Blind Method , Female , Haloperidol/adverse effects , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Psychotic Disorders/psychology , Risperidone/adverse effects
20.
Br J Psychiatry Suppl ; 41: s169-76, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11450179

ABSTRACT

BACKGROUND: The Stanley Foundation Bipolar Network (SFBN) was created to address the paucity of help studies in bipolar illness. AIMS: To describe the rationale and methods of the SFBN. METHOD: The SFBN includes five core sites and a number of affiliated sites that have adopted consistent methodology for continuous longitudinal monitoring of patients. Open and controlled studies are performed as patients' symptomatology dictates. RESULTS: The reliability of SFBN raters and the validity of the rating instruments have been established. More than 500 patients are in continuous daily longitudinal follow-up. More than 125 have been randomised to one of three of the newer antidepressants (bupropion, sertraline and venlafaxine) as adjuncts in a study of mood stabilizers and 93 to omega-3 fatty acids. A number of open clinical case series have been published. CONCLUSIONS: Well-characterised patients are followed in a detailed continuous longitudinal fashion in both opportunistic case series and double-blind, randomised controlled trials with reliable and validated measures.


Subject(s)
Antimanic Agents/therapeutic use , Bipolar Disorder/drug therapy , Multicenter Studies as Topic/methods , Humans , Longitudinal Studies , Randomized Controlled Trials as Topic/methods , Research Design
SELECTION OF CITATIONS
SEARCH DETAIL
...